Loading MEDICAMEQ price...
Peers are the listed companies in the exchange's own industry group: Pharmaceuticals. Balance-sheet figures are from the latest filed balance sheet; trends show each financial year we hold.
Latest quarterIn the quarter to June 2026 (results filed 14 Aug 2026), sales rose 11.3% from a year earlier to Rs 47.9 cr and profit rose 15.3% to Rs 1.8 cr.
- Operations used cash in FY26 (-Rs 33.2 cr) while reported profit was Rs 9.8 cr.
Each line is written by a fixed rule from the company's own filings and share price, and names the figures it uses. It describes what happened; it is not advice about the share.
Over the last 19 results, the share rose on 3 and fell on 16, and moved by 3% or more on 11.
Q1 FY27: results filed 14 Aug 2026. The share went from its close on 13 Aug 2026 to its close on 17 Aug 2026 -8.77%.
Of every Rs 100 of sales in FY26, Rs 90 went on running costs, Rs 3.6 on depreciation, Rs 1.8 on interest and Rs 1.1 on tax; Rs 5.0 was left as profit.
Thin bar: money in (sales plus other income). Thick bar: where it went. Each year is scaled to its own sales, so the bars compare shares, not size.
Per year, compounded, between financial years FY26 and the year named; only spans our filings cover. The faint bar is the latest quarter against the same quarter a year earlier. Earnings per share is not shown: filed figures are not adjusted for bonus issues and splits, so its growth would mislead.
| Measure | FY23 | FY24 | FY26 |
|---|---|---|---|
| Operating marginProfit from operations, before depreciation, interest and tax, per Rs 100 of sales. | 17.0% | 12.4% | 9.9% |
| Net marginProfit after everything, per Rs 100 of sales. | 10.4% | 5.3% | 5.0% |
| ROEProfit as a percentage of shareholders' money (from the March balance sheet). | 7.6% | 4.7% | 3.6% |
| ROCEOperating profit as a percentage of all long-term capital, owners' and lenders'. | 10.2% | 8.6% | 5.5% |
| Debt to equityBorrowings divided by shareholders' money. Lower is safer. | 0.13x | 0.15x | 0.17x |
| Interest coverHow many times operating profit covers the interest bill. Higher is safer. | 6.9x | 4.0x | 4.4x |
Each row is coloured against this company's own usual level, not against other companies: green is better than its middle year, red worse, plain is close to it. ROE, ROCE and debt rows start once the filings carry a full balance sheet (FY22 at the earliest).
At FY26 it owned Rs 372 Cr of assets. Its owners funded 74% of that and borrowings 13%.
From the March balance sheet in the company's annual filing (2026-03-31). Each bar is the full balance sheet; "everything else" is what the filed total leaves after the named lines.
In FY26 the business itself brought in Rs -33 Cr, spent Rs 5 Cr on plant and equipment, and cash rose by Rs 28 Cr over the year.
Rs 100 or more means every rupee of reported profit arrived as cash.
Full financial year to 2026-03-31, from the company's cash flow statement.
Median rather than average, so one loss-making or one very expensive peer cannot drag the reference. Valuation is shown without a colour verdict: a higher multiple can mean expensive, or faster growth expected, and only you can decide which.
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | 4.17 L cr | 34.5x | 5.0x | 14.4% | 17.9% | 0.05 | 20.2% | +10.5% | 0.94% |
| DIVISLAB Divi's Laboratories Limited | 2.40 L cr | 82.1x | 14.3x | 17.4% | 19.0% | 0.00 | 26.1% | +27.8% | 0.33% |
| TORNTPHARM Torrent Pharmaceuticals Limited | 1.73 L cr | 76.9x | 9.4x | 11.4% | - | 0.76 | 12.1% | +50.8% | 0.74% |
| ZYDUSLIFE Zydus Lifesciences Limited | 1.16 L cr | 25.9x | 4.3x | 15.5% | 19.2% | 0.40 | 16.1% | +22.0% | 0.96% |
| LAURUSLABS Laurus Labs Limited | 1.11 L cr | 101.8x | 21.0x | 20.1% | 19.7% | 0.44 | 15.0% | +29.1% | 0.08% |
| CIPLA Cipla Limited | 1.09 L cr | 32.5x | 3.2x | 9.7% | 14.9% | 0.01 | 11.8% | +2.3% | 1.18% |
| DRREDDY Dr. Reddy's Laboratories Limited | 1.09 L cr | 39.0x | 2.8x | 7.0% | - | 0.15 | 8.3% | -1.5% | 0.61% |
| MANKIND Mankind Pharma Limited | 95,486 cr | 46.8x | 5.9x | 12.5% | 13.7% | 0.38 | 14.0% | +12.9% | 0.04% |
| AUROPHARMA Aurobindo Pharma Limited | 91,489 cr | 24.8x | 2.4x | 9.8% | 13.6% | 0.20 | 10.6% | +16.3% | 0.25% |
| LUPIN Lupin Limited | 89,616 cr | 16.2x | 4.0x | 24.7% | 28.4% | 0.26 | 18.5% | +32.0% | 0.61% |
| GLENMARK Glenmark Pharmaceuticals Limited | 62,812 cr | 35.0x | 6.0x | 17.1% | 16.2% | 0.00 | 10.1% | +23.1% | 0.22% |
| ALKEM Alkem Laboratories Limited | 60,134 cr | 27.9x | 4.3x | 15.4% | 18.8% | 0.11 | 14.6% | +10.9% | 1.02% |
| BIOCON Biocon Limited | 53,581 cr | 97.3x | 1.6x | 1.1% | 2.9% | 0.40 | 2.4% | +10.0% | 0.17% |
| IPCALAB IPCA Laboratories Limited | 49,182 cr | 37.5x | 6.1x | 14.4% | 16.4% | 0.07 | 13.6% | +20.8% | 0.11% |
| GLAND Gland Pharma Limited | 46,913 cr | 41.5x | 4.5x | 10.9% | 13.7% | 0.02 | 16.8% | +19.6% | 0.63% |
| AJANTPHARM Ajanta Pharma Limited | 42,381 cr | 37.2x | 9.4x | 25.1% | 29.4% | 0.05 | 19.6% | +24.8% | 0.83% |
| GLAXO GlaxoSmithKline Pharmaceuticals Limited | 41,436 cr | 38.8x | 18.3x | 46.8% | 55.4% | 0.00 | 27.0% | +16.6% | 1.72% |
| EMCURE Emcure Pharmaceuticals Limited | 33,767 cr | 33.4x | 6.8x | 20.5% | 25.1% | 0.24 | 10.5% | +22.9% | 0.17% |
| SAILIFE Sai Life Sciences Limited | 30,682 cr | 85.4x | 12.3x | 14.6% | 18.1% | 0.04 | 16.1% | +11.7% | 0.00% |
| WOCKPHARMA Wockhardt Limited | 29,316 cr | 71.8x | 5.9x | 7.8% | 6.5% | 0.40 | 11.6% | +25.9% | 0.00% |
| PPLPHARMA Piramal Pharma Limited | 25,906 cr | - | 3.2x | -3.8% | 0.8% | 0.67 | -3.4% | +17.4% | 0.07% |
| RUBICON Rubicon Research Limited | 24,647 cr | 84.9x | 19.1x | 22.4% | 24.3% | 0.20 | 14.9% | - | 0.00% |
| NEULANDLAB Neuland Laboratories Limited | 24,582 cr | 49.1x | 13.1x | 26.6% | 23.1% | 0.10 | 21.0% | +119.2% | 0.06% |
| GRANULES Granules India Limited | 20,333 cr | 30.5x | 4.0x | 13.0% | 16.0% | 0.26 | 11.8% | +22.0% | 0.18% |
| COHANCE Cohance Lifesciences Limited | 17,735 cr | 115.6x | 4.5x | 2.6% | 4.8% | 0.04 | 3.9% | -23.1% | 0.00% |
| SHILPAMED Shilpa Medicare Limited | 17,620 cr | 59.0x | 6.8x | 11.5% | 12.4% | 0.25 | 17.7% | +44.9% | 0.06% |
| CAPLIPOINT Caplin Point Laboratories Limited | 17,282 cr | 26.1x | 4.8x | 18.7% | 22.0% | 0.00 | 29.6% | +19.6% | 0.26% |
| PFIZER Pfizer Limited | 16,869 cr | 30.9x | 4.0x | 17.5% | 22.9% | 0.00 | 28.6% | +8.3% | 4.46% |
| ONESOURCE Onesource Specialty Pharma Limited | 16,019 cr | - | 2.8x | -0.8% | 0.5% | 0.22 | -3.1% | +37.2% | 0.00% |
| ALIVUS Alivus Life Sciences Limited | 15,490 cr | 25.7x | 4.7x | 18.1% | 21.8% | 0.00 | 23.3% | +6.4% | 0.40% |
| ERIS Eris Lifesciences Limited | 15,318 cr | 23.5x | 3.9x | 17.1% | 15.7% | 0.59 | 20.6% | +13.0% | 0.00% |
| ASTRAZEN AstraZeneca Pharma India Limited | 15,129 cr | 174.2x | 17.3x | 19.4% | 25.5% | 0.00 | 7.0% | +29.7% | 0.53% |
| APLLTD Alembic Pharmaceuticals Limited | 15,064 cr | 21.7x | 2.6x | 12.2% | 12.8% | 0.24 | 8.9% | +25.7% | 1.44% |
| JUBLPHARMA Jubilant Pharmova Limited | 14,805 cr | 42.3x | 2.1x | 5.0% | 6.4% | 0.45 | 4.1% | +17.3% | 0.54% |
| NATCOPHARM Natco Pharma Limited | 14,145 cr | 12.4x | 1.5x | 12.4% | 16.3% | 0.08 | 32.9% | -44.7% | 0.64% |
| CONCORDBIO Concord Biotech Limited | 13,717 cr | 50.3x | 6.8x | 13.5% | 16.6% | 0.00 | 24.6% | +26.2% | 0.82% |
| ACUTAAS Acutaas Chemicals Limited | 13,708 cr | 71.3x | 8.3x | 22.6% | 27.7% | 0.02 | 26.5% | +59.1% | 0.09% |
| MARKSANS Marksans Pharma Limited | 13,443 cr | 26.0x | 4.5x | 17.1% | 17.5% | 0.01 | 16.4% | +35.6% | 0.27% |
| CORONA CORONA Remedies Limited | 12,485 cr | 62.7x | 16.7x | 26.6% | 29.3% | 0.19 | 13.5% | - | 0.00% |
| MEDICAMEQ Medicamen Biotech Limited | 357 cr | 35.5x | 1.3x | 3.6% | 5.5% | 0.17 | 5.0% | +11.3% | 0.38% |
Swipe the table sideways for more columns. Tap a heading to sort. A dash means the figure is not filed or cannot be worked out for that company. A bigger cohort is cut to its 40 largest companies.
Operating margin has gone from 17.0% to 9.9% over these years - the share of every rupee of sales kept after running costs, before interest and tax. Full financial years only, so a part-year is never shown as a whole one. Hover any year for its complete figures.
The share of traded quantity that was actually delivered (not squared off intraday) - high delivery vs its 20-session average suggests real buying or holding, not just churn.
Insider trading data unavailable.
Announcements unavailable.
Backtest an equity strategy on real market data, free - no card needed.
Equity price, fundamentals and realized volatility are end-of-day / quarterly from real market data. The option chain (PCR, max pain, expected move, IV, OI) is live from the exchange during market hours; outside them it shows the last session's close. Shareholding, insider trades and announcements are the company's own exchange filings. Analysis only, not investment advice.